# Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

> **NCT01244490** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 338 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Extended-release Guanfacine Hydrochloride
- **DRUG:** Atomoxetine Hydrochloride
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT01244490
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-17
- **Primary completion:** 2013-05-01
- **Final completion:** 2013-05-01
- **Target enrollment:** 338 (ACTUAL)
- **Last updated:** 2021-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01244490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01244490, "Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01244490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*